VistaGen Therapeutics (VTGN) reported Q2 revenue
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Join SI Premium – FREE
VistaGen Therapeutics (NASDAQ: VTGN) reported Q2 EPS of ($0.54). Revenue for the quarter came in at $258 million.
For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
- Corona-maker Constellation Brands beats estimates, shares jump 2%
- Wolfe Research Upgrades FOX Corp. (FOXA) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
